UGT76E9 Antibody

What is UGT76E9 Antibody and what is its molecular target?

UGT76E9 Antibody is a monoclonal antibody designed to specifically recognize and bind to UGT76E9, an enzyme belonging to the UDP-glycosyltransferase family. This enzyme participates in the glycosylation of various small molecules and plays significant roles in cellular metabolism. The antibody typically recognizes specific epitopes within the protein structure, enabling detection of UGT76E9 across various experimental platforms.

Methodologically, when using this antibody, it's essential to understand that its recognition capabilities depend on the epitope accessibility, which can vary depending on protein folding, post-translational modifications, and experimental conditions. Validation using positive and negative controls helps confirm target specificity before proceeding with experiments .

How does UGT76E9 Antibody structure influence its binding properties?

The UGT76E9 Antibody, like other monoclonal antibodies, features a characteristic Y-shaped structure composed of two heavy chains and two light chains connected by disulfide bonds. Each antibody contains variable regions at the tips of the Y structure that create unique binding pockets specific to UGT76E9 epitopes.

From a methodological perspective, this structural arrangement determines binding affinity, avidity, and specificity. The complementarity-determining regions (CDRs) within the variable domains form the antigen-binding site through a combination of hydrogen bonds, van der Waals forces, and hydrophobic interactions. These structural features enable researchers to predict binding behavior under different experimental conditions and troubleshoot issues related to specificity and sensitivity .

What expression systems are used to produce functional UGT76E9 Antibody?

UGT76E9 Antibody can be produced through several expression systems, each with distinct advantages for research applications:

• Hybridoma technology: Mouse B cells are fused with myeloma cells to create hybridomas that secrete monoclonal antibodies with high specificity toward UGT76E9

• Recombinant expression: DNA sequences encoding the antibody are inserted into expression vectors for production in:

  • Mammalian cells (CHO, HEK293): Offer proper folding and post-translational modifications

  • Bacterial systems (E. coli): Provide cost-effective production but lack glycosylation

  • Insect cells: Balance between proper folding and production efficiency

When selecting an expression system, researchers should consider how production method affects antibody characteristics such as glycosylation patterns, which can influence binding properties and stability .

How can sequence analysis confirm UGT76E9 Antibody specificity?

Sequence analysis of UGT76E9 Antibody provides critical information about its binding specificity and potential cross-reactivity. Modern approaches involve:

• Variable region sequencing to identify CDRs responsible for epitope recognition

• Comparison with databases of known antibody sequences to assess uniqueness

• In silico analysis to predict binding affinity and potential cross-reactivity

• Epitope mapping to confirm interaction with the target protein

This methodological approach helps researchers understand the molecular basis of antibody-antigen interaction and predict experimental performance. Data mining of patent and research databases can provide valuable insights into similar antibodies and their applications, informing experimental design and validation strategies .

What validation experiments confirm UGT76E9 Antibody target specificity?

Comprehensive validation of UGT76E9 Antibody specificity requires multiple complementary approaches:

Thorough validation is essential as recent studies have highlighted problems with antibody cross-reactivity that can impact data relevancy and result in wasted research resources .

What are optimal experimental conditions for UGT76E9 Antibody in immunoblotting?

Optimization of experimental conditions for UGT76E9 Antibody in immunoblotting requires systematic testing of multiple parameters:

• Sample preparation: Lysis buffer composition significantly affects epitope accessibility

  • RIPA buffer: Good for membrane proteins but may denature some epitopes

  • NP-40 buffer: Milder, preserves protein-protein interactions

  • SDS buffer: Strongest denaturation, exposes hidden epitopes

• Blocking conditions:

  • 5% BSA in TBST: Recommended for phospho-specific antibodies

  • 5% non-fat milk: Effective for many applications but contains phospho-proteins

  • Commercial blocking buffers: May reduce background in challenging samples

• Antibody dilution and incubation:

  • Primary antibody: Typically 1:500-1:2000, overnight at 4°C

  • Secondary antibody: Typically 1:5000-1:10000, 1 hour at room temperature

• Detection method:

  • Chemiluminescence: High sensitivity, wide dynamic range

  • Fluorescence: Allows multiplexing and precise quantification

Experimental design must follow statistical principles to ensure reproducibility and validity of results, with proper controls and replicates .

How should researchers design experiments to investigate UGT76E9 localization?

Designing experiments to investigate UGT76E9 localization requires careful planning and appropriate controls:

• Fixation method selection:

  • Paraformaldehyde (4%): Preserves most cellular structures

  • Methanol: Better for some nuclear antigens

  • Glyoxal: Alternative with reduced autofluorescence

• Permeabilization optimization:

  • Triton X-100 (0.1-0.5%): Standard for most applications

  • Saponin (0.1%): Gentler, preserves membranes

  • Digitonin (10-50 μg/ml): Selective permeabilization of plasma membrane

• Antibody validation controls:

  • Secondary-only control: Detects non-specific binding

  • Isotype control: Accounts for non-specific Fc receptor binding

  • Peptide competition: Confirms epitope specificity

  • Knockout/knockdown samples: Ultimate negative control

• Colocalization studies:

  • Selection of appropriate markers for subcellular compartments

  • Quantitative analysis using correlation coefficients

  • Super-resolution techniques for detailed localization

This methodological framework ensures that localization data is reliable and reproducible, following principles of sound experimental design .

How can researchers resolve contradictory data when using UGT76E9 Antibody?

When faced with contradictory data using UGT76E9 Antibody, researchers should implement a systematic troubleshooting approach:

• Antibody validation reassessment:

  • Verify lot-to-lot consistency with manufacturer's validation data

  • Reconfirm specificity using knockout/knockdown controls

  • Test alternative antibody clones recognizing different epitopes

• Technical variables analysis:

  • Sample preparation differences (buffer composition, incubation times)

  • Detection method sensitivity and dynamic range

  • Image acquisition and analysis parameters

• Biological variables consideration:

  • Cell/tissue type differences in target expression or modification

  • Experimental conditions affecting target expression or localization

  • Post-translational modifications altering epitope accessibility

• Resolution strategies:

  • Orthogonal techniques to confirm findings (e.g., mass spectrometry)

  • Multiple antibody approach targeting different epitopes

  • Genetic tagging to avoid antibody specificity issues altogether

This methodological framework helps researchers identify sources of variability and resolve contradictory results .

What controls are essential when using UGT76E9 Antibody for quantitative applications?

Quantitative applications using UGT76E9 Antibody require rigorous controls to ensure accuracy and reliability:

These controls are essential elements of experimental design that ensure the validity and reproducibility of quantitative data, following established principles of scientific research methodology .

How does sample preparation affect UGT76E9 Antibody binding efficiency?

Sample preparation significantly impacts UGT76E9 Antibody binding efficiency through multiple mechanisms:

• Protein extraction methods:

  • Mechanical disruption: Preserves most epitopes but may be incomplete

  • Detergent-based lysis: Efficiency depends on detergent type and concentration

  • Sonication: Can damage some epitopes through localized heating

  • Freeze-thaw cycles: May affect protein structure and epitope accessibility

• Buffer composition effects:

  • Salt concentration: Affects ionic interactions between antibody and antigen

  • pH: Alters protein charge and conformation

  • Detergent type: Influences protein solubilization and epitope exposure

  • Protease inhibitors: Prevent epitope degradation

• Fixation considerations for microscopy:

  • Chemical fixatives can modify or mask epitopes

  • Cross-linking fixatives may reduce accessibility

  • Fixation duration affects penetration and epitope preservation

• Storage conditions:

  • Freeze-thaw cycles can degrade epitopes

  • Storage buffer composition affects long-term stability

  • Temperature fluctuations may cause protein denaturation

Understanding these methodological factors helps researchers optimize protocols for maximum antibody binding efficiency and reliable results .

How can UGT76E9 Antibody be adapted for high-throughput screening applications?

Adapting UGT76E9 Antibody for high-throughput screening requires optimization across several parameters:

• Miniaturization strategies:

  • Microplate format optimization (96, 384, or 1536-well)

  • Reduction of reaction volumes (5-20 μL per well)

  • Automated liquid handling for consistent delivery

• Assay development considerations:

  • Homogeneous (no-wash) formats to reduce steps

  • Time-resolved fluorescence for improved signal-to-noise ratio

  • Multiplexed detection with orthogonal antibodies

• Validation metrics:

  • Z'-factor determination (>0.5 indicates robust assay)

  • Signal-to-background ratio optimization (>5:1 preferred)

  • Intra- and inter-plate variability assessment (<15% CV)

• Data analysis:

  • Automated image analysis for high-content screening

  • Machine learning algorithms for pattern recognition

  • Statistical models for hit identification and validation

This methodological approach can be implemented using automated platforms that significantly increase throughput while maintaining data quality, enabling screening of large compound libraries or genetic perturbations .

What are the cutting-edge applications of UGT76E9 Antibody in single-cell analysis?

UGT76E9 Antibody has emerging applications in single-cell analysis that provide unprecedented resolution of cellular heterogeneity:

• Mass cytometry (CyTOF) applications:

  • Metal-conjugated antibodies enable simultaneous detection of 40+ proteins

  • Minimal spectral overlap compared to fluorescence-based methods

  • Deep profiling of UGT76E9 in relation to other cellular markers

• Single-cell proteogenomics:

  • CITE-seq for simultaneous protein and RNA detection

  • Integration with spatial transcriptomics for tissue context

  • Correlation of UGT76E9 protein levels with gene expression

• Imaging mass cytometry:

  • Subcellular localization with 1 μm resolution

  • Tissue microenvironment analysis

  • Quantitative assessment of UGT76E9 expression in distinct cell populations

• Microfluidic approaches:

  • Droplet-based single-cell isolation

  • Integrated proteomic and genomic analysis

  • High-throughput screening of cellular responses

These cutting-edge methodologies enable researchers to investigate UGT76E9 expression and function with unprecedented resolution, revealing cell-to-cell variability that may be masked in bulk analyses .

How can researchers optimize UGT76E9 Antibody for super-resolution microscopy?

Optimizing UGT76E9 Antibody for super-resolution microscopy requires specific considerations to achieve nanometer-scale resolution:

• Labeling strategies:

  • Direct fluorophore conjugation: Minimizes size but may reduce signal

  • Secondary antibody approach: Amplifies signal but increases linkage error

  • Fab fragments: Reduce size while maintaining specificity

  • Site-specific labeling: Controls fluorophore position relative to binding site

• Fluorophore selection:

  • Photostability: Critical for techniques requiring multiple image frames

  • Photoswitching capabilities: Essential for STORM/PALM approaches

  • Brightness: Determines localization precision

  • Spectral characteristics: Affects multicolor imaging capabilities

• Sample preparation refinements:

  • Optimal fixation to preserve nanoscale structures

  • Clearing techniques to reduce background

  • Index-matching media to minimize aberrations

  • Post-fixation to stabilize antibody binding

• Imaging parameters:

  • Buffer composition for optimal fluorophore performance

  • Acquisition settings to maximize localization precision

  • Drift correction for long acquisitions

  • Reconstruction algorithms appropriate for specific techniques

These methodological refinements enable visualization of UGT76E9 localization and interactions at nanometer-scale resolution, revealing details impossible to discern with conventional microscopy .

What strategies can overcome epitope masking in complex samples when using UGT76E9 Antibody?

Overcoming epitope masking in complex samples requires strategic approaches to enhance UGT76E9 Antibody accessibility:

• Antigen retrieval methods:

  • Heat-induced epitope retrieval (HIER): Breaks protein cross-links

    • Citrate buffer (pH 6.0): Mild retrieval conditions

    • EDTA buffer (pH 8.0-9.0): Stronger retrieval for difficult epitopes

    • Tris-EDTA buffer: Balanced approach for many applications

  • Enzymatic epitope retrieval: Digests masking proteins

    • Proteinase K: Aggressive treatment for heavily fixed samples

    • Trypsin: Milder digestion for selected applications

• Detergent-based approaches:

  • Triton X-100 (0.1-1%): Disrupts hydrophobic interactions

  • SDS (0.1-0.5%): Strong detergent for resistant samples

  • Saponin (0.1%): Permeabilizes membranes while preserving structure

• Denaturing conditions:

  • Urea (2-8M): Disrupts protein folding to expose hidden epitopes

  • Guanidinium hydrochloride: Strong chaotropic agent

  • Heat treatment: Partial unfolding to increase accessibility

• Sequential staining strategies:

  • Primary antibody cocktails: Optimized for compatibility

  • Cyclic immunofluorescence: Multiple rounds of staining and elution

  • Signal amplification: Tyramide signal amplification for weak signals

These methodological approaches help researchers detect UGT76E9 in challenging samples where epitopes may be masked by fixation, protein-protein interactions, or complex matrix effects .

How can UGT76E9 Antibody be integrated with proteomics workflows?

Integration of UGT76E9 Antibody with proteomics workflows creates powerful approaches for studying protein function and interactions:

• Immunoprecipitation-mass spectrometry (IP-MS):

  • Standard IP-MS: Identifies UGT76E9 interactors

  • RIME (Rapid Immunoprecipitation Mass spectrometry of Endogenous proteins): Captures protein complexes

  • Cross-linking IP-MS: Stabilizes transient interactions

  • Proximity-dependent biotinylation: Maps protein neighborhoods

• Antibody-based fractionation:

  • Immunodepletion: Removes abundant proteins to detect low-abundance species

  • Sequential immunoprecipitation: Isolates specific protein subcomplexes

  • Immuno-SILAC: Quantifies dynamic interactions

• Targeted proteomics:

  • SISCAPA (Stable Isotope Standards and Capture by Anti-Peptide Antibodies): Quantifies specific peptides

  • Parallel reaction monitoring: Targeted quantification with high specificity

  • Antibody-guided data acquisition: Focuses analysis on proteins of interest

• Spatial proteomics:

  • Imaging mass cytometry: Maps protein distribution in tissues

  • CODEX (CO-Detection by indEXing): Highly multiplexed tissue imaging

  • Digital spatial profiling: Quantitative spatial analysis

These integrated approaches combine the specificity of antibody-based detection with the depth and breadth of proteomic analysis, enabling comprehensive characterization of UGT76E9 function in biological systems .

What are systematic approaches to troubleshoot non-specific binding of UGT76E9 Antibody?

Non-specific binding is a common challenge when working with antibodies that can be addressed through systematic optimization:

• Blocking optimization:

  • Test different blocking agents:

    • BSA (1-5%): Pure protein, minimal interference

    • Non-fat milk (1-5%): Effective but contains phospho-proteins

    • Commercial blockers: Formulated for specific applications

  • Adjust blocking duration (1-2 hours at room temperature or overnight at 4°C)

  • Include blocking additives (normal serum from secondary antibody species)

• Antibody dilution refinement:

  • Perform titration experiments to identify optimal concentration

  • Balance signal intensity against background

  • Consider extended incubation with more dilute antibody solution

• Washing protocol enhancement:

  • Increase wash buffer stringency (higher salt concentration)

  • Extend washing duration and number of washes

  • Add detergents (0.1-0.5% Tween-20) to reduce hydrophobic interactions

• Sample preparation modifications:

  • Pre-adsorb antibody with tissues/cells lacking target

  • Use additives to reduce non-specific interactions (0.1-1% BSA in antibody diluent)

  • Implement pre-clearing steps to remove sticky components

This methodical approach helps researchers eliminate non-specific binding that can compromise experimental results and lead to misinterpretation of data .

How can researchers address batch-to-batch variability in UGT76E9 Antibody performance?

Addressing batch-to-batch variability requires proactive strategies to ensure consistent experimental results:

• Comparative validation:

  • Side-by-side testing of old and new batches

  • Quantitative assessment of key performance parameters

  • Documentation of optimal working conditions for each batch

• Reference standard establishment:

  • Creation of internal reference samples for validation

  • Standardized positive and negative controls

  • Determination of batch-specific working dilutions

• Lot reservation strategies:

  • Purchase of multiple vials from single lot for long-term studies

  • Aliquoting to minimize freeze-thaw cycles

  • Proper storage with consistent conditions

• Alternative approaches when variability is unavoidable:

  • Multiple antibody validation (different clones or suppliers)

  • Recombinant antibodies with consistent production

  • Genetic tagging approaches to avoid antibody use

These methodological approaches help researchers maintain experimental consistency despite the inherent variability in antibody production, ensuring reliable and reproducible results across studies .

What methods can determine the optimal UGT76E9 Antibody concentration for different applications?

Determining optimal antibody concentration requires systematic titration across applications:

For each application, a systematic approach involves:

• Initial broad-range titration to identify working range

• Fine-tuning within identified range

• Inclusion of appropriate controls at each dilution

• Quantitative assessment of performance metrics

• Determination of optimal concentration balancing sensitivity and specificity

This methodological framework enables researchers to optimize antibody usage across applications while minimizing reagent consumption and maximizing data quality .

How should researchers interpret unexpected molecular weight bands when using UGT76E9 Antibody?

Interpreting unexpected molecular weight bands requires systematic investigation of potential biological and technical causes:

• Biological explanations:

  • Post-translational modifications (glycosylation, phosphorylation, ubiquitination)

  • Alternative splicing variants

  • Proteolytic processing (cleavage products)

  • Protein complexes (incompletely denatured)

  • Closely related family members (cross-reactivity)

• Technical considerations:

  • Sample preparation artifacts (degradation, aggregation)

  • Incomplete reduction of disulfide bonds

  • Non-specific binding to abundant proteins

  • Secondary antibody cross-reactivity

  • Loading or transfer issues

• Validation approaches:

  • Compare with positive control samples

  • Test in knockout/knockdown systems

  • Pretreat samples to modify specific PTMs

  • Perform peptide competition assays

  • Use mass spectrometry to identify unexpected bands

• Reporting recommendations:

  • Document all observed bands

  • Provide molecular weight markers

  • Include positive and negative controls

  • Specify expected molecular weight based on sequence

  • Discuss potential explanations for discrepancies

This structured approach helps researchers determine whether unexpected bands represent meaningful biological variation or technical artifacts, ensuring accurate data interpretation .

What strategies can extend the shelf-life and maintain activity of UGT76E9 Antibody?

Maintaining antibody activity requires careful attention to storage and handling conditions:

• Storage optimization:

  • Temperature: Store at -20°C for long-term preservation or 4°C for working solutions

  • Aliquoting: Divide into single-use portions to minimize freeze-thaw cycles

  • Buffer composition: Include stabilizers like glycerol (50%) or BSA (1 mg/ml)

  • Preservatives: Sodium azide (0.02-0.05%) prevents microbial growth

• Handling practices:

  • Minimize freeze-thaw cycles (ideally <5 times)

  • Allow to warm to room temperature before opening

  • Centrifuge briefly after thawing to collect contents

  • Use clean pipette tips to prevent contamination

• Stabilization techniques:

  • Addition of cryoprotectants (trehalose, glycerol)

  • pH optimization (typically pH 7.2-7.8)

  • Addition of carrier proteins (BSA, gelatin)

  • Protection from light for fluorophore-conjugated antibodies

• Monitoring approaches:

  • Regular validation against reference samples

  • Activity testing before critical experiments

  • Visual inspection for signs of aggregation or contamination

  • Documentation of performance over time

These methodological approaches help researchers maximize the usable lifetime of antibody reagents, ensuring consistent experimental results and reducing costs associated with premature degradation .

How can UGT76E9 Antibody be utilized in multiplex detection systems?

UGT76E9 Antibody can be integrated into multiplex detection systems through several methodological approaches:

• Spectral multiplexing strategies:

  • Fluorophore conjugation with spectrally distinct dyes

  • Quantum dot labeling for narrow emission profiles

  • Metal-tagged antibodies for mass cytometry

  • Sequential elution and reprobing for cyclic immunofluorescence

• Spatial multiplexing approaches:

  • Microarray-based detection with positional encoding

  • Barcoded bead systems for suspension arrays

  • Multiplexed ion beam imaging (MIBI) for tissue analysis

  • Digital spatial profiling with region selection

• Temporal multiplexing methods:

  • Time-resolved fluorescence with lanthanide chelates

  • Sequential detection with antibody stripping

  • Microfluidic delivery of antibodies in defined sequence

  • Real-time monitoring with different acquisition windows

• Combinatorial detection systems:

  • Antibody cocktails with compatible clones

  • Orthogonal labeling strategies (e.g., antibody + nucleic acid probe)

  • Multi-epitope ligands with distinct detection modalities

  • Machine learning algorithms for signal deconvolution

These methodological approaches enable simultaneous detection of UGT76E9 alongside other targets of interest, providing contextual information about its expression, localization, and function in complex biological systems .

What emerging technologies are enhancing UGT76E9 Antibody specificity and sensitivity?

Emerging technologies are dramatically improving antibody performance through various innovative approaches:

• Antibody engineering advancements:

  • Phage display selection for enhanced affinity and specificity

  • CDR optimization through directed evolution

  • Yeast display for rapid screening of variants

  • Computational design for enhanced binding properties

• Novel detection technologies:

  • Proximity ligation assay for enhanced specificity

  • Single-molecule detection methods

  • Surface plasmon resonance for real-time binding analysis

  • Digital ELISA platforms with attomolar sensitivity

• Signal amplification strategies:

  • Enzymatic amplification (tyramide signal amplification)

  • Rolling circle amplification for nucleic acid-linked antibodies

  • Branched DNA technology for signal enhancement

  • Nanoparticle-based amplification systems

• Microarray advancements:

  • High-density protein arrays for cross-reactivity testing

  • Peptide arrays for epitope mapping

  • Tissue microarrays for rapid screening

  • Cell-based arrays for functional validation

These technological innovations significantly enhance the performance of antibody-based detection systems, enabling researchers to study UGT76E9 with unprecedented sensitivity and specificity, even in challenging samples with low target abundance .

How does UGT76E9 Antibody perform in tissue microenvironment studies?

UGT76E9 Antibody applications in tissue microenvironment studies require specialized methodologies to maintain spatial context:

• Tissue processing considerations:

  • Fixation optimization to preserve antigenicity

  • Sectioning techniques (frozen vs. paraffin)

  • Tissue clearing methods for 3D imaging

  • Multi-region sampling for heterogeneous tissues

• Spatial analysis approaches:

  • Multiplex immunohistochemistry with spectral unmixing

  • In situ proximity ligation for protein interaction analysis

  • Spatial transcriptomics correlation with protein expression

  • 3D reconstruction from serial sections

• Microenvironment characterization:

  • Cell type identification with lineage markers

  • Extracellular matrix component analysis

  • Signaling pathway activation assessment

  • Correlation with physiological or pathological features

• Quantitative spatial analytics:

  • Cell-by-cell quantification of expression levels

  • Neighborhood analysis of cellular interactions

  • Topological data analysis of spatial patterns

  • Deep learning approaches for pattern recognition

These methodological approaches enable researchers to study UGT76E9 expression and function within the complex spatial context of tissues, providing insights into its role in normal physiology and disease processes .

What are the considerations for using UGT76E9 Antibody in clinical research applications?

Clinical research applications of UGT76E9 Antibody require additional considerations to ensure reliability and reproducibility:

• Validation requirements:

  • Expanded validation across diverse sample types

  • Verification in clinical specimens with varying preservation methods

  • Correlation with clinical parameters and outcomes

  • Establishment of reference ranges and cutoff values

• Standardization approaches:

  • Use of calibrated reference standards

  • Implementation of standardized protocols

  • Participation in proficiency testing programs

  • Documentation following regulatory guidelines

• Quality control measures:

  • Inclusion of appropriate control samples

  • Batch effect monitoring and correction

  • Inter-laboratory validation studies

  • Long-term stability assessment

• Analytical considerations:

  • Quantitative scoring methods development

  • Statistical approaches for clinical correlation

  • Machine learning algorithms for complex pattern recognition

  • Integration with other clinical and molecular data

These methodological frameworks ensure that UGT76E9 Antibody-based assays meet the rigorous requirements of clinical research, producing reliable data that can inform scientific understanding and potentially clinical decision-making .

How can computational approaches enhance UGT76E9 Antibody-based research?

Computational approaches significantly enhance antibody-based research through multiple methodological innovations:

• Antibody informatics:

  • Sequence analysis to predict binding properties

  • Structural modeling of antibody-antigen interactions

  • Epitope prediction algorithms

  • Cross-reactivity assessment tools

• Image analysis advancements:

  • Automated quantification of staining patterns

  • Deep learning for feature extraction

  • 3D reconstruction from optical sections

  • Registration of multimodal imaging data

• Systems biology integration:

  • Network analysis of protein interactions

  • Pathway enrichment in co-expression datasets

  • Multi-omics data integration

  • Temporal modeling of dynamic processes

• Machine learning applications:

  • Pattern recognition in complex datasets

  • Predictive modeling of experimental outcomes

  • Anomaly detection for quality control

  • Transfer learning across related experiments

These computational approaches transform antibody-based research from primarily descriptive to predictive and mechanistic, enabling researchers to extract maximum value from experimental data and design more efficient follow-up studies guided by computational insights .